// App-Quantinova.ai

5553 : A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.

Researchers

Presenter

  • Roisin Eilish O'Cearbhaill

Principal Investigators

  • Sacha Gnjatic

  • Carol Aghajanian

  • Alexia Iasonos

  • Jason A. Konner

  • Nicolle Losada

  • Debra Sarasohn

  • Teresa Rasalan

  • William P. Tew

  • Dmitriy Zamarin

  • Phillip Wong

  • Paul Sabbatini

Medical Centers

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Glasgow prognostic score

  • Granulocyte-macrophage-colony stimulating factor

  • Immunoglobulin G

  • WT1 Transcription Factor

Drug/Treatment

  • Nivolumab

  • GM-CSF

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02737787

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved